TY - JOUR
T1 - Statins and autoimmunity
T2 - State-of-the-art
AU - Dehnavi, Sajad
AU - Sohrabi, Nasrollah
AU - Sadeghi, Mahvash
AU - Lansberg, Peter
AU - Banach, Maciej
AU - Al-Rasadi, Khalid
AU - Johnston, Thomas P.
AU - Sahebkar, Amirhossein
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/1
Y1 - 2020/1
N2 - HMG-CoA reductase inhibitors, or statins, are potent plasma LDL-cholesterol (LDL-c) lowering agents. Since the introduction of the first statin, lovastatin, in 1987, accumulating evidence showed that non-cholesterol lowering effects play an important role in their efficacy to reduce atherosclerotic cardiovascular disease (ASCVD). Thus, these non-LDL-c lowering properties could benefit patients with immune-mediated diseases. Statins and their associated immune-modulating roles have recently received much attention. Different statins have been administered in various experimental and clinical studies focused on autoimmunity. The results indicate that statins can modulate immune responses through mevalonate pathway-dependent and -independent mechanisms. The anti-inflammatory and immune-modulating effects include cell adhesion, migration of antigen presenting cells, and differentiation, as well as activation, of T-cells. In various autoimmune diseases (e.g. rheumatoid arthritis, lupus, and multiple sclerosis), promising results have been obtained to date.
AB - HMG-CoA reductase inhibitors, or statins, are potent plasma LDL-cholesterol (LDL-c) lowering agents. Since the introduction of the first statin, lovastatin, in 1987, accumulating evidence showed that non-cholesterol lowering effects play an important role in their efficacy to reduce atherosclerotic cardiovascular disease (ASCVD). Thus, these non-LDL-c lowering properties could benefit patients with immune-mediated diseases. Statins and their associated immune-modulating roles have recently received much attention. Different statins have been administered in various experimental and clinical studies focused on autoimmunity. The results indicate that statins can modulate immune responses through mevalonate pathway-dependent and -independent mechanisms. The anti-inflammatory and immune-modulating effects include cell adhesion, migration of antigen presenting cells, and differentiation, as well as activation, of T-cells. In various autoimmune diseases (e.g. rheumatoid arthritis, lupus, and multiple sclerosis), promising results have been obtained to date.
KW - Autoimmune diseases
KW - Immunomodulation
KW - Statins
UR - http://www.scopus.com/inward/record.url?scp=85087122122&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087122122&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/393cbda1-b161-3bae-ae5d-9a2fe7fe860c/
U2 - 10.1016/j.pharmthera.2020.107614
DO - 10.1016/j.pharmthera.2020.107614
M3 - Article
C2 - 32592715
AN - SCOPUS:85087122122
SN - 0163-7258
VL - 214
SP - 107614
JO - Pharmacology and Therapeutics
JF - Pharmacology and Therapeutics
M1 - 107614
ER -